Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
40.50
-0.32 (-0.78%)
At close: Apr 24, 2026, 4:00 PM EDT
40.50
0.00 (0.00%)
After-hours: Apr 24, 2026, 5:17 PM EDT
Travere Therapeutics Employees
Travere Therapeutics had 497 employees as of December 31, 2025. The number of employees increased by 112 or 29.09% compared to the previous year.
Employees
497
Change (1Y)
112
Growth (1Y)
29.09%
Revenue / Employee
$987,380
Profits / Employee
-$51,400
Market Cap
3.74B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 497 | 112 | 29.09% |
| Dec 31, 2024 | 385 | 5 | 1.32% |
| Dec 31, 2023 | 380 | -82 | -17.75% |
| Dec 31, 2022 | 462 | 152 | 49.03% |
| Dec 31, 2021 | 310 | 48 | 18.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Alumis | 224 |
| Structure Therapeutics | 220 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 146 |
| Tango Therapeutics | 137 |
TVTX News
- 10 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 10 days ago - FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients - Benzinga
- 10 days ago - US FDA expands approval for Travere Therapeutics' drug for rare kidney disease - Reuters
- 11 days ago - Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS - Business Wire
- 2 months ago - Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 2 months ago - Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 2 months ago - Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit - Business Wire
- 3 months ago - TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewsWire